Do we really understand pimecrolimus?

JACC Cardiovasc Interv. 2009 Oct;2(10):1025-7. doi: 10.1016/j.jcin.2009.08.007.
No abstract available

Publication types

  • Comment
  • Editorial

MeSH terms

  • Angioplasty, Balloon, Coronary / adverse effects
  • Angioplasty, Balloon, Coronary / instrumentation*
  • Animals
  • Cardiovascular Agents / administration & dosage*
  • Coated Materials, Biocompatible
  • Coronary Restenosis / etiology*
  • Coronary Restenosis / pathology
  • Coronary Stenosis / pathology
  • Coronary Stenosis / therapy*
  • Drug-Eluting Stents*
  • Humans
  • Hyperplasia
  • Polymers
  • Prosthesis Design
  • Risk Assessment
  • Severity of Illness Index
  • Tacrolimus / administration & dosage
  • Tacrolimus / analogs & derivatives*
  • Time Factors
  • Treatment Outcome
  • Xylenes

Substances

  • Cardiovascular Agents
  • Coated Materials, Biocompatible
  • Polymers
  • Xylenes
  • parylene
  • pimecrolimus
  • Tacrolimus